Downloading...
Download

Novartis

Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone. Target #1 = $110.00 Target #2 = $120.00
NYSE:NVSLong
by WorthlessViews
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but also setting new standards in innovation and sustainability. A strong monthly demand imbalance at $97.13 per share has recently taken control. Expecting a decent reaction from this price level in the following weeks.
NYSE:NVSLong
by AlfonsoMoreno
Bullish on Novartis. NVSImmediate targets 94, 95. Invalidation 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:NVSLong
by Rykin_Capital
Calling bullish on Novartis. NVSLooks like we have a an end to a zigzag here. Technically, we have not left FibChannel, hence the approach is risky. If the picture is right, we may see one or more impulses upwards. Wait and see. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:NVSLong
by Rykin_Capital
NOVARTIS AG, NVS - 4.0% in 35 daysI understand the euphoria of picking on a winning horse and getting returns in excess of or even more than 100%, but what you need to pay attention to is money management and managing your positions. You can buy stocks, you can buy futures, you can buy bonds and you can buy and/or sell options. The key is always to use the instruments that we feel confident in and to have the ideal timing. It is never just one of these two individually. In this case, we have opened a position in our portfolio on Novartis (NVS), which will surely generate us a 4% return within a month. Our goal is always a monthly return between 4%/5% monthly which on a compound growth we get an average of 50%/60% annually. NYSE:NVS
NYSE:NVS
by SwissTradingSchool
Novartis: Buy opportunity with split entry.NVS was among the high cap losers yesterday on the renewed coronavirus tensions and pulled back dramatically (-6.90%). This however can be the buy opportunity of the next several months as it hit the 1D MA200 (orange line) and is approaching the Higher Low trend line of the 1W Channel Up (RSI = 45.378, MACD = 1.640, ADX = 65.865). Even though the MACD indicated the possibility of a deeper pull to the 84.00 1W Support before a meaningful rebound, we give equal probabilities for the rebound to start within the Higher Low zone. Our Target zone is 98.00 - 100.00. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:NVSLong
by InvestingScope
You looking to buy Tilray TLRY? My guess for an entry point Tilray TLRY just blow up in mid 2018 and lost from its highs around 80%. We are currently at around 70$ and Ill guess it will drop another 35% from here, to see it close the Gap at around 45$. Tilray has only 76 Mil. shares outstanding and around 15% of it is in free float. Thats also the reason why it took off so extremely. The less shares are available the more pressure is to the upside of the price when people want to get in. They have a pretty strong investors background that is supporting the company and I think it will be a hughe player in the future of the cannabiz. They make strategic investments and cooperations like the Anheuser, Novartis or the Sandoz Deals. They are GMP certified and allowed to ship their product to Europe. They do not make stupid acquisitions like most of the other companies just to say "we bought something over there and over there" what will eventually never pay out. They don't need to wash money like Aphria (buying companies, that were bought private by the insiders of the company which bought it for a penny and sold it for a gold coin to Aphria to cash them selfs a nice bag), because they are already rich. I see a bright future but on the 19th of January the insiders are allowed to sell their shares and that will make the price drop. So that's why I am waiting at least until the 20th to see how the stock behaves and I consider to buy at 45$. Just my opinion so make your own research. And like always MAI THE MARKETS BE WITH YOU
NASDAQ:TLRYLong
by derfreietrader
1
Novartis almost a buyPharmaceutical stocks represents a defensive asset when a positive market cycle is about to finish or when it is foreseen a cycle less positive than the previous one. In such context pharma stocks should have an advantage because of inelastic demand for such goods. Novartis ($NVS,$NOVN) is one of the candidate to break up as the price is moving in a triangle since 2015. the stock doesn't not have an high volatility as other stocks but is one of the main represented of INDEX STOCK HEALTH CARE. There are nice technical indications on the chart that a breakout might happen in the next weeks. At the moment I am expecting a price pullback, where at the end it will be possible to go for an entry long. Conclusions At the moment price is consolidating and some other days to reduce RSI value will be needed. It's possible either to open positions at the end of the pullback or when price breaks out the downtrend (2015). Possibility to have it in CHF or $.
SIX:NOVN
by TRADOMICS_